


# PRODUCT INFORMATION



**PD 153035**

Item No. 18080

**CAS Registry No.:** 153436-54-5  
**Formal Name:** N-(3-bromophenyl)-6,7-dimethoxy-4-quinazolinamine  
**Synonyms:** AG-1517, NSC 669364, SU 5271  
**MF:** C<sub>16</sub>H<sub>14</sub>BrN<sub>3</sub>O<sub>2</sub>  
**FW:** 360.2  
**Purity:** ≥98%  
**UV/Vis.:** λ<sub>max</sub>: 222, 255, 346 nm  
**Supplied as:** A crystalline solid  
**Storage:** -20°C  
**Stability:** ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

## Laboratory Procedures

PD 153035 is supplied as a crystalline solid. A stock solution may be made by dissolving the PD 153035 in the solvent of choice, which should be purged with an inert gas. PD 153035 is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide. The solubility of PD 153035 in these solvents is approximately 0.2, 2, and 0.3 mg/ml, respectively.

PD 153035 is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, PD 153035 should first be dissolved in DMSO and then diluted with the aqueous buffer of choice. PD 153035 has a solubility of 0.11 mg/ml in a 1:8 solution of DMSO:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

## Description

PD 153035 is a potent, reversible inhibitor of epidermal growth factor receptor (EGFR) kinase ( $K_i = 5.2 \text{ pM}$ ;  $IC_{50} = 29 \text{ pM}$ ).<sup>1</sup> It less effectively inhibits HER2 ( $IC_{50} = 2.3 \text{ }\mu\text{M}$ ) and has little effect on several other receptor and non-receptor tyrosine kinases.<sup>1</sup> PD 153035 has been shown to rapidly suppress autophosphorylation of EGFR in fibroblasts and human epidermoid carcinoma cells, as well as to selectively block EGF-mediated cellular processes, including mitogenesis and early gene expression.<sup>2,3</sup>

## References

1. Fry, D.W., Kraker, A.J., McMichael, A., *et al.* A specific inhibitor of the epidermal growth factor receptor tyrosine kinase. *Science* **265**(5175), 1093-1095 (1994).
2. Bos, M., Mendelsohn, J., Kim, Y.-M., *et al.* PD153035, a tyrosine kinase inhibitor, prevents epidermal growth factor receptor activation and inhibits growth of cancer cells in a receptor number-dependent manner. *Clin. Cancer Res.* **3**(11), 2099-2106 (1997).
3. Rae, J.M. and Lippman, M.E. Evaluation of novel epidermal growth factor receptor tyrosine kinase inhibitors. *Breast Cancer Res. Treat.* **83**(2), 99-107 (2004).

### WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

### SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

### WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 10/31/2022

## CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD

ANN ARBOR, MI 48108 · USA

**PHONE:** [800] 364-9897

[734] 971-3335

**FAX:** [734] 971-3640

CUSTSERV@CAYMANCHEM.COM

WWW.CAYMANCHEM.COM